Another Trial Blow for Lilly: Alimta Combo Regimen Fails in Phase III for NSCLC

Drug Industry Daily
A A
Eli Lilly’s Phase III trial of a drug combination to treat nonsquamous non-small cell lung cancer (NSCLC) missed its primary endpoint of overall survival — the second trial setback for Lilly in as many weeks.

To View This Article:

Login

Subscribe To Drug Industry Daily